Axcan Pharma－xofyne65

Axcan Pharma

N) is nearing an agreement to acquire specialty pharmaceutical company Aptalis Holdings Inc from private equity firm TPG Capital LP for about $3 billion, a person familiar with the& . Privately-held Aptalis, which had sales of $688 million in the year ended September 2013,& .. Private-equity firm TPG purchased Aptalis, at the time called Axcan Pharma Inc....Forest Laboratories, hungry for sales to replace its flailing antidepressant Lexapro, has sewn up a $2. axcan pharma The fund held a& .TPG Capital, unable to find a buyer willing to pay its $3 billion-plus asking price for Aptalis Pharma, is now going the IPO route, with a filing made Thursday that would allow TPG to extract at least part of its investment in the& .90 billion, expanding its presence in the gastrointestinal and cystic fibrosis markets..TPG Capital`s stalled sale process for drugmaker Aptalis Pharma could be back on after it emerged previously interested party Forest Laboratories was nearing a $3bn buyout..Reuters – Forest Laboratories Inc (FRX..

.Reuters – Forest Laboratories Inc (FRX..., in 2008 for about $1. A deal announcement could come as soon as& . Axcan later& .9 billion deal for the specialty drugmaker Aptalis.(Reuters) – Aptalis Pharma Inc, a specialty drugmaker owned by private equity firm TPG Capital LP, has appointed underwriters for an initial public offering after efforts to sell the company failed, people familiar with the matter&

A deal announcement could come as soon as& . Axcan later& .9 billion deal for the specialty drugmaker Aptalis.(Reuters) – Aptalis Pharma Inc, a specialty drugmaker owned by private equity firm TPG Capital LP, has appointed underwriters for an initial public offering after efforts to sell the company failed, people familiar with the matter& ..Clayton Dubilier & Rice is just short of a $5 billion target for Clayton Dubilier & Rice Fund IX LP and plans to close the vehicle at its $6 billion hard cap by the end of the first quarter, Michael Wursthorn reports. for $2..3bn in 2007, when it was known as Axcan Pharma, before merging it with Euran Pharmaceuticals in 2011 and renaming it Aptalis

Clayton Dubilier & Rice is just short of a $5 billion target for Clayton Dubilier & Rice Fund IX LP and plans to close the vehicle at its $6 billion hard cap by the end of the first quarter, Michael Wursthorn reports. for $2..3bn in 2007, when it was known as Axcan Pharma, before merging it with Euran Pharmaceuticals in 2011 and renaming it Aptalis.3 billion.N) is nearing an agreement to acquire specialty pharmaceutical company Aptalis Holdings Inc from private equity firm TPG Capital LP for about $3 billion, a person familiar with the& . Privately-held Aptalis, which had sales of $688 million in the year ended September 2013,& .. Private-equity firm TPG purchased Aptalis, at the time called Axcan Pharma Inc